Vertellus acquires CENTAURI technologies and rebrands as Aurorium
28 Jul 2023
Acquisition
Aurorium, formerly Vertellus, has announced the acquisition of CENTAURI Technologies. The addition of CENTAURI’s complementary specialty material product portfolio and advanced manufacturing capabilities expands Aurorium’s offering and extends its reach.
In addition to the acquisition, the company announced that it has changed its official name from Vertellus to Aurorium. Aurorium’s refreshed brand identity better represents the company’s growth and evolution as a global materials innovation partner with a diversified portfolio of specialty ingredients and performance-enhancing materials.
CENTAURI is a technology driven manufacturer of specialty materials, serving a global customer in its production facility in Pasadena, Texas. CENTAURI’s specific expertise in hydroformylation and hydrogenation processes, including high pressure, high melt, and other complex capabilities, is highly complementary to Aurorium’s strategy and strengthens its position as a provider of specialty ingredients and performanceenhancing materials. CENTAURI is the sixth acquisition Aurorium has completed since 2019, following Bercen Chemicals, Chemtrade Life Sciences, IM Chemical, Jarchem Innovative Ingredients, and Polyscope Polymers.
John Van Hulle, Aurorium CEO, said “CENTAURI is an exciting addition to Aurorium as we continue to expand our presence in specialty ingredients and materials. CENTAURI adds a complementary portfolio of high-quality solutions, differentiated manufacturing capabilities, and an impressive track record of innovation and growth. With CENTAURI’s customer-focused approach and exceptional engineering capabilities joining our platform, Aurorium is well-positioned to capitalise on growth across our end markets.”
Kyle Killebrew, CENTAURI CEO, commented, “We believe that Aurorium is the ideal strategic partner for the next phase of CENTAURI’s growth. We will be able to leverage Aurorium’s global resources to enhance our product offering, expand into new geographies and end markets, and grow our manufacturing capacity so that we can continue to deliver superior service and capabilities for our customers.”
Thomas Chadwick, principal at Pritzker Private Capital, added, “This acquisition is an excellent strategic fit with Aurorium’s rebranding and continued focus on specialty products. We look forward to continuing to support the Aurorium and CENTAURI teams as they serve customers with innovative, high-quality products and services.”
Based in Indianapolis, with 1,400+ employees located across North America, Europe, and Asia, Aurorium produces specialty ingredients and performance-enhancing materials designed to enhance quality of life, support health and wellness, and deliver value-add solutions. The company serves an expanding portfolio of customers globally across multiple markets.
As part of its refreshed brand identity, Aurorium identified five fundamental principles that underpin the company’s culture, values, and commitment to its customers, colleagues, and communities:
Differentiation: Helping companies prosper in their marketplaces, enhance their products, and achieve optimal performance
Expertise: Bringing deep industry knowledge and technical experience, adding value to our customers
Innovation: Unique solutions and specialty formulations fostered by creative, dynamic, and collaborative partnerships
Presence: Global reach with a deep, diverse portfolio, coupled with a focus on sustainability and safety
Customer Experience: Through flexibility, integrity, and a can-do attitude, Aurorium aims to bring unparalleled levels of service, reliability, and trust to customers
“Our new name and identity, Aurorium, better represents the strength of our platform and growth opportunity for our business,” said Faye Freeman, president of Aurorium. “As Aurorium, we are well-positioned to expand our products and markets, and more effectively serve our customers with a wide range of solutions that are essential to their businesses. Aurorium is committed to delivering a best-in-class customer experience, innovative solutions, and dynamic partnerships to help our customers thrive in an increasingly competitive global marketplace.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.